The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions

Biochemical and Biophysical Research Communications

Volumn 398, Issue 1, 2010, Pages 74-78

  Mylonis, Ilias ^a   Lakka, Achillia ^a   Tsakalof, Andreas ^a   Simos, George ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Flavonoids; Hepatocellular carcinoma; HIF 1 ; Huh7; Hypoxia; Hypoxia inducible factor 1; Kaempferol; MAPK

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; DIET; FLAVONOIDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KAEMPFEROLS; LIVER NEOPLASMS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3;

EID: 77954818547     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.038     Document Type: Article

References (25)

1. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
2. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
3. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
4. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
5. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
6. Wu X.Z., Xie G.R., Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007, 22:1178-1182.
7. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009, 29:625-634.
8. Poon E., Harris A.L., Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 2009, 11:e26.
9. Huang G.W., Yang L.Y., Lu W.Q. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J. Gastroenterol. 2005, 11:1705-1708.
10. Tanaka H., Yamamoto M., Hashimoto N., Miyakoshi M., Tamakawa S., Yoshie M., Tokusashi Y., Yokoyama K., Yaginuma Y., Ogawa K. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res. 2006, 66:11263-11270.
11. Yao D.F., Jiang H., Yao M., Li Y.M., Gu W.J., Shen Y.C., Qiu L.W., Wu W., Wu X.H., Sai W.L. Quantitative analysis of hepatic hypoxia-inducible factor-1alpha and its abnormal gene expression during the formation of hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2009, 8:407-413.
12. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., Georgatsou E., Bonanou S., Simos G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J. Biol. Chem. 2006, 281:33095-33106.
13. Mylonis I., Chachami G., Paraskeva E., Simos G. A typical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. J. Biol. Chem. 2008, 283:27620-27627.
14. Triantafyllou A., Mylonis I., Simos G., Bonanou S., Tsakalof A. Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic. Biol. Med. 2008, 44:657-670.
15. Abramoff M.D., Magelhaes P.J., Ram S.J. Image Processing with Image. J. Biophot. Int. 2004, 11:36-42.
16. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
17. McCarty M.F., Barroso-Aranda J., Contreras F. Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med. Hypotheses 2010, 74:789-797.
18. Liu F., Wang P., Jiang X., Tan G., Qiao H., Jiang H., Krissansen G.W., Sun X. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci. 2008, 99:2055-2061.
19. Garcia-Maceira P., Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28:313-324.
20. Marfe G., Tafani M., Indelicato M., Sinibaldi-Salimei P., Reali V., Pucci B., Fini M., Russo M.A. Kaempferol induces apoptosis in two different cell lines via Akt inactivation Bax and SIRT3 activation and mitochondrial dysfunction. J. Cell. Biochem. 2009, 106:643-650.
21. Jeong J.C., Kim M.S., Kim T.H., Kim Y.K. Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem. Res. 2009, 34:991-1001.
22. Luo H., Rankin G.O., Liu L., Daddysman M.K., Jiang B.H., Chen Y.C. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr. Cancer 2009, 61:554-563.
23. Gates M.A., Tworoger S.S., Hecht J.L., De Vivo I., Rosner B., Hankinson S.E. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int. J. Cancer 2007, 121:2225-2232.
24. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr 2005, 81:230S-242S.
25. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch. Biochem. Biophys. 2008, 476:107-112.